Skip to main content

Does Genvoya make you gain weight?

Medically reviewed by Leigh Ann Anderson, PharmD. Last updated on May 5, 2025.

Official Answer by Drugs.com

Key Points

What’s in Genvoya?

Genvoya (elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide), from Gilead Sciences is an oral prescription medicine used to treat human immunodeficiency virus (HIV) in adults and children who are at least 12 years old and who weigh at least 55 pounds (25 kilograms). HIV-1 is the virus that causes AIDS (Acquired Immune Deficiency Syndrome).

Genvoya is considered a complete, one pill regimen for HIV treatment. It is taken once-a-day with food and you do not need to use other HIV-1 medicines with Genvoya. It contains 4 different types of drugs:

Table 1: Drugs found in Genvoya

Ingredient Class Mechanism of Action
Elvitegravir Integrase strand transfer inhibitor (INSTI) Blocks the action of the integrase (an enzyme) that facilitates insertion of the HIV virus into the cell.
Emtricitabine (Emtriva) Nucleoside analog reverse transcriptase inhibitor (NRTI) Blocks the action of reverse transcriptase and inhibits viral replication.
Tenofovir alafenamide (TAF) - (Vemlidy) Nucleoside analog reverse transcriptase inhibitor (NRTI) Blocks the action of reverse transcriptase and inhibits viral replication.
Cobicistat (Tybost) CYP3A inhibitor pharmacokinetic enhancer (booster) Given to help increase blood levels of other HIV medications, such as elvitegravir. Does not treat HIV.

Research on weight gain with Genvoya

Recent studies have suggested that newer HIV treatments, including ones that contain integrase strand inhibitors (INSTIs) such as bictegravir, dolutegravir or elvitegravir, may be linked with weight gain in patients living with HIV. Elvitegravir is one of the medicines found in Genvoya.

A 2019 meta-analysis published in Clinical Infectious Diseases reported on weight gain with INSTIs. Investigators looked for an association between demographic factors, antiretroviral therapy (ART), disease-specific variables, and weight gain in previously untreated (treatment-naïve) people living with HIV. The group included roughly 5,600 patients who received treatment between 2003 and 2015. The study population was 88% male and 62% white.

Drugs evaluated included:

When looking at all treatments, researchers found each study group showed some weight gain. The overall median weight gain of 2 kg (4.4 lbs) occurred primarily in the first year of treatment (48 weeks) in 12.8% of treatment-naïve patients. Over a 2 year period, 17.3% of participants gained weight but 30.2% had weight loss.

Statistically significant risk factors linked to weight gain (over about one year) included:

Related questions

Genvoya weight gain

Elvitegravir (and other integrase inhibitors) as well as tenofovir alafenamide (TAF), both components of Genvoya, were associated with weight gain in this analysis.

Table 1: Weight Gain with Integrase Inhibitors

Integrase inhibitor Mean weight gain (at 96 weeks)
*Table adapted from Sax, et al. 2019
bictegravir (BIC) 4.24 kg [9.2 lbs] (95% CI, 3.71–4.78 kg)
dolutegravir (DTG) 4.07 kg [9 lbs] (95% CI, 3.51–4.62 kg)
cobicistat-boosted elvitegravir (EVG/c) 2.72 kg [6 lbs] (95% CI, 2.45–3 kg)

Does tenofovir alafenamide (TAF) cause weight gain?

Stribild contains elvitegravir, emtricitabine, and the original form of tenofovir known as tenofovir disoproxil fumarate (TDF). When TDF was compared with the newer tenofovir alafenamide (TAF), more weight gain was seen with TAF (4.2 kg) than with TDF (2 kg) at 96 weeks.

Elvitegravir / cobicistat was also associated with a significantly higher odds of more than a 10% weight gain (OR 1.32, 1.04-1.78, p=0.026) when compared to efavirenz.

However, investigators did not find a link between >10% weight gain and metabolic effects such as increased blood sugar (hyperglycemia) or type 2 diabetes. In addition, obesity at study entry was not found to be a risk factor for weight gain in the meta-analysis.

Bottom Line

References

Read next

Does Genvoya cause erectile dysfunction?

Erectile dysfunction is not reported to be a side effect of Genvoya, a medication used to treat human immunodeficiency virus (HIV)-1 infection. Genvoya is a four-drug combination tablet containing cobicistat, elvitegravir, emtricitabine and tenofovir alafenamide. Continue reading

Triumeq vs Genvoya. How do they compare?

Both Triumeq and Genvoya are combination one-tablet-a-day medicines that are considered first-line treatments for HIV-1 by the HHS guidelines. Because Triumeq does not contain cobicistat, an antiviral booster, it is less likely to interact with other medications and may have fewer side effects than Genvoya. People taking Genvoya do not need to be tested for the HLA-B*5701 gene, because it does not contain abacavir. Continue reading

Can I drink alcohol with Genvoya?

There is no interaction between Genvoya and alcohol, so most people can drink alcohol in moderation while on Genvoya. Excessive alcohol use on its own may increase HIV disease progression... Continue reading

See also:

Related medical questions

Drug information

Related support groups